Low molecular weight heparin-loaded polymeric nanoparticles: Formulation, characterization, and release characteristics

Drug Development and Industrial Pharmacy

Volumn 28, Issue 9, 2002, Pages 1091-1099

  Hoffart, V ^a   Ubrich, N ^a   Simonin, C ^a   Babak, V ^a   Vigneron, C ^a   Hoffman, M ^a   Lecompte, T ^b   Maincent, P ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b CHU NANCY BRABOIS   (France)

Author keywords

Biodegradable polymer; Drug delivery; Eudragit; Low molecular weight heparin; Nanoparticle; W O W emulsion

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BUFFER; CHROMOGENIC SUBSTRATE; EMULSIFYING AGENT; ESTERASE; EUDRAGIT; EUDRAGIT RS; LOW MOLECULAR WEIGHT HEPARIN; NANOCAPSULE; NANOPARTICLE; OIL; ORGANIC SOLVENT; PHOSPHATE; POLYCAPROLACTONE; POLYGLACTIN; POLYMER; TINZAPARIN; WATER; ACRYLIC ACID RESIN; ANTITHROMBIN III; BIOMATERIAL; DRUG CARRIER; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ARTICLE; BIODEGRADABILITY; CHEMICAL COMPOSITION; DEVICE; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; EMULSION; EVAPORATION; MICROENCAPSULATION; SURFACE PROPERTY; ULTRASOUND; VISCOSITY; CHEMISTRY; KINETICS; NANOTECHNOLOGY; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; TIME;

ACRYLIC RESINS; ADMINISTRATION, ORAL; ANTITHROMBIN III; BIOCOMPATIBLE MATERIALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; HEPARIN, LOW-MOLECULAR-WEIGHT; KINETICS; LACTIC ACID; NANOTECHNOLOGY; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; TIME FACTORS;

EID: 0036411727     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-120014576     Document Type: Article

References (23)

1. Hirsh, J.; Warkentin, T.E.; Raschke, R.; Granger, C.; Ohman, E.M.; Dalen, J.E. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1998, 114, 489S-510S.
2. Carter, C.J.; Kelton, J.G.; Hirsh, J.; Cerskus, A.; Santos, A.V.; Gent, M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982, 59, 1239-1245.
3. Sobel, M.; McNeill, P.M.; Carlson, P.L.; Kermode, J.C.; Adelman, B.; Conroy, R.; Marques, D. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J. Clin. Invest. 1991, 87, 1787-1793.
4. Handeland, G.F.; Abildgaard, U.; Holm, H.A.; Arnesen, K.E. Dose adjusted heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin. Eur. J. Clin. Pharmacol. 1990, 39, 107-112.
5. Brzu, T.; Molho, P.; Tobelem, G.; Petitou, M.; Caen, J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim. Biophys. Acta 1985, 845, 196-203.
6. Ginsberg, J.S.; Kowalchuck, G.; Hirsh, J.; Brill-Edwards, P.; Burrows, R.; Coates, G.; Webber, C. Heparin effect on bone density. Thromb. Haemost. 1990, 64, 286-289.
7. Morton, A.K.; Edwards, H.E.; Allen, J.C.; Phillips, G.O. An Evaluation of the Oral Administration of Commercial and Fractionated Heparin Samples in Rats. Int. J. Pharm. 1981, 9, 321-325.
8. Dal Pozzo, A.; Acquasaliente, M.; Geron, M.R. New heparin complexes active by intestinal absorption. I. Multiple ion pairs with basic organic compounds. Thromb. Res. 1989, 56, 119-124.
9. Tidball, C.S.; Lipman, R.I. Enhancement of jejunal absorption of heparinoid sodium ethylenediaminetetraacetate in the dog. Proc. Soc. Exp. Biol. Med. 1962, 111, 713-715.
10. Guarini, S.; Ferrari, W. Olive oil-provoked bile dependent absorption of heparin from the gastrointestinal tract in rats. Pharm. Res. Commun. 1985, 17, 685-694.
11. Ueno, M.; Nakasaki, T.; Horikoshi, I.; Sakuragawa, N. Oral administration of liposomally-entrapped heparin to beagle dogs. Chem. Pharm. Bull. 1982, 30, 2245-2247.
12. Steiner, S.; Rosen, R. Delivery System for Pharmacological Agents Encapsulated with Proteinoids. U.S. Patent 4,925,673, 15 May 1990.
13. Leone-Bay, A.; Paton, D.; Variano, B.; Leipold, H.; Rivera, T.; Miura-Fraboni, J.; Baughman, R.A.; Santiago, N.J. Acylated non-α-amino acids as novel agents for the oral delivery of heparin sodium, USP. Control. Rel. 1998, 50, 41-49.
14. Gonze, M.D.; Salartash, K.; Sternbergh, W.C.; Baughman, R.A.; Leone-Bay, A.; Money, S.R. Orally administered unfractionated heparin with carrier agent is therapeutic for deep vein thrombosis. Circulation 2000, 101, 2658-2661.
15. Baughman, R.A.; Kapoor, S.C.; Agarwal, R.K.; Kisicki, J.; Catella-Lawson, F.; FitzGerald, G.A. Oral delivery of anticoagulant doses of heparin, a randomized, double blind controlled study in humans. Circulation 1998, 98, 1610-1615.
16. Money, S.R.; York, J.W. Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis. Cardiovasc. Surg. 2001, 9 (3), 211-218.
17. Jiao, Y.; Ubrich, N.; Marchand-Arvier, M.; Vigneron, C.; Hoffman, M.; Maincent, P. Preparation and in vitro evaluation of heparin-loaded polymeric nanoparticles. Drug Del. 2001, 8, 135-141.
18. Jiao, Y.; Ubrich, N.; Marchand-Arvier, M.; Vigneron, C.; Hoffman, M.; Lecompte, T.; Maincent, P. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002, 105, 230-235.
19. Alex, R.; Bodmeier, R. Encapsulation of Water-Soluble Drugs by a Modified Solvent Evaporation Method. I. Effect of Process and Formulation Variables on Drug Entrapment. J. Microencaps. 1989, 7, 347-355.
20. Ardry, M. Dosage de l'héparine: Étude critique. Bull. Ordre 1967, 135, 699-708.
21. Teien, A.N.; Lie, M. Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb. Res. 1977, 10, 399-410.
22. Jiao, Y.; Ubrich, N.; Hoffart, V.; Marchand-Arvier, M.; Vigneron, C.; Hoffman, M.; Maincent, P. Preparation and characterization of heparin-loaded polymeric microparticles. Drug Dev. Ind. Pharm. 2002, 28(8), 1033-1041.
23. Polakovic, M.; Görner, T.; Gref, R.; Dellacherie, E. Lidocaine loaded biodegradable nanospheres. II. Modelling of drug release. J. Contr. Rel. 1999, 60, 169-177.